Homocysteine: What Your Level Means and How to Lower It

Key Takeaways

Homocysteine has had a strange career. In the 1990s it looked like the next cholesterol: an amino acid that tracked heart attacks and strokes, could be lowered cheaply with B vitamins, and seemed to sit on a causal pathway. Then a decade of large randomised trials lowered it by a quarter in tens of thousands of people — and heart attacks did not budge.

That history explains why people still get a homocysteine result back with no clear instruction. This guide covers what the number measures, what pushes it up, how far B vitamins bring it down, and what the trials show that lowering it actually does — for the heart, for stroke and for the brain. The practical plan built on it is the Methylation Support Protocol.

What Homocysteine Is

Every methylation reaction in the body — DNA, neurotransmitters, phospholipids, creatine — runs on methyl groups donated by S-adenosylmethionine. Once it donates, what remains becomes homocysteine. The body has two ways to clear it:

1. Re-methylation back to methionine. The main route uses 5-methyl-folate as the methyl donor and vitamin B12 as the cofactor. A backup route in the liver and kidney uses betaine (TMG).
2. Transsulfuration to cysteine. A one-way route that needs vitamin B6, and that matters most after a protein-heavy meal.

Folate production depends on the MTHFR enzyme, which needs riboflavin (B2) as its cofactor. So four B vitamins and betaine all feed into one number. When any of them is short, homocysteine rises — which is exactly why it is a useful alarm.

What Is a "Normal" Level?

In the Hordaland Homocysteine Study of over 16,000 Norwegians, average fasting homocysteine was 10.8 µmol/L in men and 9.1 µmol/L in women aged 40–42, rising to 12.3 and 11.0 at age 65–67. Most laboratories flag values above about 15 µmol/L, and clinical associations are usually seen above that level — but the relationship with risk is continuous, with no clean threshold.

The sample needs care. Homocysteine leaks out of blood cells if the tube sits at room temperature, so a falsely high result can come from slow processing. A single high value is worth repeating before it changes anything.

What Raises Homocysteine

The 18,000-person Hordaland data and the trials point to a short list of causes. Most are more important than the number itself.

• Vitamin B12 deficiency. The commonest treatable cause, especially in people over 60, vegans, and anyone on long-term metformin or acid suppression. Pair homocysteine with serum B12 and, if borderline, methylmalonic acid, which rises in B12 deficiency but not folate deficiency. See Vitamin B12.
• Low folate. Less common where flour is fortified, still common where it is not.
• Reduced kidney function. The kidney clears homocysteine; creatinine was one of the strongest determinants in Hordaland.
• Age and male sex. Both raise it independently.
• Smoking. Heavy-smoking men aged 65–67 averaged 4.8 µmol/L higher than never-smoking women aged 40–42.
• Unfiltered coffee. A litre a day of French-press coffee for two weeks raised homocysteine by 10% in a randomised crossover trial. Filtered coffee is less clear.
• Metformin. In a meta-analysis of 12 randomised trials, metformin raised homocysteine by about 2 µmol/L when no B vitamins were given — and lowered it slightly when they were.
• Overt hypothyroidism. Raised levels fall with thyroid replacement.
• MTHFR 677TT. Mostly when folate or riboflavin status is low. The full picture is in MTHFR Variants: What the Evidence Actually Supports.

How Far B Vitamins Lower It

This part of the story is settled. Two meta-analyses of randomised trials from the Homocysteine Lowering Trialists' Collaboration give the dose-response:

0.4 mg gets about 90% of the maximum effect; 0.8 mg gets essentially all of it. Adding about 0.4–0.5 mg of B12 takes off a further 7%. B6 adds nothing to fasting levels. Effects are larger when the starting level is higher or folate status lower — a typical result is a fall from about 12 to 8–9 µmol/L.

Two other levers are smaller and more specific. Betaine at 4 g/day or more lowered homocysteine by 1.2 µmol/L in a meta-analysis of five small trials — see TMG. Riboflavin at 1.6 mg/day lowered it by 22% in a 2006 trial, but only in people with the MTHFR 677TT genotype, and by 40% in those who started with low riboflavin status.

What Lowering It Does: The Heart

Here is the part that changed the field. Between 2004 and 2010, six large trials randomised people at high cardiovascular risk to B vitamins or placebo.

The 2017 Cochrane review pooled 15 trials in 71,422 people: myocardial infarction RR 1.02, all-cause death RR 1.01, both judged high-quality evidence, and the trial-sequential analysis concluded more trials are unlikely to change that. An individual-participant meta-analysis of 37,485 people reached the same answer and found no excess of cancer.

There was also a warning. In NORVIT, the arm given folic acid, B12 and B6 had a borderline increase in events (RR 1.22, P = 0.05), and the investigators advised against the treatment. HOPE-2 saw more hospitalisations for unstable angina (RR 1.24). Cochrane's estimate for serious adverse events was RR 1.07 (1.00–1.14). None of this is alarming at nutritional doses, but it is a reason not to treat homocysteine with the largest pills on the shelf.

Why did the trials fail when the observational data looked so strong? The best answer came from genetics. A 2012 analysis of 48,175 coronary cases in unpublished MTHFR datasets found that people genetically programmed for lifelong higher homocysteine had no excess coronary risk (OR 1.02). The earlier positive genetic studies had been inflated by publication bias. Homocysteine tracks heart disease because the things that raise it — kidney decline, smoking, age, poor diet — also cause heart disease.

The cardiovascular reason to measure homocysteine is to find those causes — not to supplement the number down. For the markers that do predict and respond, see ApoB and Lp(a).

What Lowering It Does: Stroke

Stroke is the one cardiovascular outcome where B vitamins show a benefit, and the benefit depends on geography.

The China Stroke Primary Prevention Trial randomised 20,702 adults with hypertension to enalapril alone or enalapril plus 0.8 mg folic acid for a median 4.5 years. First stroke fell from 3.4% to 2.7% — HR 0.79 (0.68–0.93) — with no effect on heart attacks or mortality. The Cochrane review puts the overall stroke effect at RR 0.90 (0.82–0.99), and estimates 143 people treated for 5.4 years to prevent one stroke.

A 2024 meta-analysis of 21 trials explains the spread. Where flour is not fortified, folic acid cut stroke by 17% (RR 0.83); in fortified countries the effect was nil (RR 1.04), and the difference between the two was statistically significant. The genetic data agree: the MTHFR TT genotype raised stroke risk by 68% in Asia and not at all in fortified regions.

So if you live in the United States, Canada or Australia and eat bread, your folate status is probably already where the trials would have taken it. In most of Europe and Asia, where fortification is not mandatory, a raised homocysteine with low folate is a more meaningful finding.

What Lowering It Does: The Brain

The brain story is the most contested. The VITACOG trial gave 271 adults over 70 with mild cognitive impairment folic acid 0.8 mg, B12 0.5 mg and B6 20 mg, or placebo, for two years. Brain atrophy slowed from 1.08% to 0.76% a year, and by 53% in those starting above 13 µmol/L. A follow-up MRI analysis found up to sevenfold less grey-matter loss in regions affected by Alzheimer's disease — but only in people whose homocysteine was above the median of 11 µmol/L. A further analysis found the benefit appeared only when omega-3 status was good: with high omega-3, 33% on B vitamins versus 59% on placebo progressed on a dementia rating scale.

Against that: these are surrogate outcomes and post-hoc subgroups from a single small trial, and the lead investigators hold patents in the area. A meta-analysis of 11 trials with cognitive data on 22,000 people found no effect on cognitive ageing — enough to rule out a slowing of more than a month per year. Most of those participants were not selected for high homocysteine or cognitive impairment.

The fair reading: a possible benefit for older adults with mild cognitive impairment, raised homocysteine and adequate omega-3 — and no evidence for anyone else. That is why the neuroprotection protocol monitors homocysteine and corrects a raised level with B12 and folate rather than adding them for everyone.

What to Do With Your Result

1. Repeat a single high value with a properly processed fasting sample.
2. Look for the cause. Serum B12 (with methylmalonic acid if 150–300 pmol/L), folate, creatinine/eGFR, TSH, medication list (metformin, acid suppressants), smoking and coffee habits.
3. Correct what you find. B12 deficiency is the important one — untreated it causes nerve damage that folate can mask. See Vitamin B12.
4. If no cause and the level is raised, 0.4–0.8 mg of folate plus about 0.5 mg of B12 will bring it down by roughly a quarter. Methylfolate and folic acid both work — see Methylfolate. Add riboflavin if you know you are MTHFR TT.
5. Retest at 8–12 weeks. If it has not fallen, look harder for a cause rather than adding more vitamins.
6. Keep perspective. For heart attack prevention, blood pressure, ApoB, smoking and exercise matter; homocysteine does not.

Frequently Asked Questions

Is high homocysteine dangerous? It is a marker of things that are. On its own, lowering it has not prevented heart attacks or deaths in trials. It may modestly reduce stroke where folate intake is low.

Should I take B6 to lower homocysteine? Not for fasting homocysteine — it adds nothing in the meta-analyses. High-dose B6 also causes nerve damage with long-term use. See Vitamin B6.

Do I need methylated B vitamins? No. Folic acid and cyanocobalamin lowered homocysteine in the trials. Methylated forms are an acceptable alternative.

Does TMG help? Modestly: about 1.2 µmol/L at 4 g/day or more. It is a backup pathway, not a first-line treatment.

What is the target? There is no trial-validated target. Bringing a raised level back into the typical range by correcting its cause is the reasonable aim.

Related Research

• The Methylation Support Protocol
• MTHFR Variants: What the Evidence Actually Supports
• The Methylation Support Protocol: Test, Then Target
• Vitamin B12
• Methylfolate
• ApoB and Lp(a): The Cardiovascular Markers That Matter
• The Biohacker's Blood Panel: 40 Biomarkers